PharmacoEconomics & Outcomes News 792, p28 - 2 Dec 2017 Sitagliptin add-on therapy cost saving for T2DM in Italy Sitagliptin added on to metformin is a cost-saving alternative to sulfonylurea add-on therapy for the management of patients with type 2 diabetes mellitus (T2DM) in Italy. This is the main finding of a cost-consequence analysis conducted to assess the economic impact of using sitagliptin, compared with sulfonylureas, as second-line therapy in add-on to metformin for a hypothetical cohort of 100 000 patients with T2DM not achieving glycaemic control with metformin monotherapy. The analysis was conducted from the Italian National Health Service (INHS) and a societal perspective. The data analysis showed that use of sitagliptin as add-on to metformin was cost saving from both the INHS and a societal perspective, generating savings of €51 846 442 and €61 217 723, respectively, over a 3-year time horizon. The researchers note that the higher drug acquisition costs related to sitagliptin + metformin therapy (€83 387 970) were offset by other costs for disease management at 3 years of follow-up, in particular due to lower use of devices for blood glucose self-monitoring, a lower incidence of hypoglycaemia and cardiovascular (CV) events, and a delay to insulin switch. The analysis also showed that use of sitagliptin would avoid 26 882 non-severe hypoglycaemic events, 6528 severe hypoglycaemic events and 1562 major CV events. * The study was supported by Merck Sharp & Dohme. Lorenzoni V, et al. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. ClinicoEconomics and Outcomes Research : 20 Nov 2017. Available from: URL: https:// doi.org/10.2147/CEOR.S141477 803285955 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera